Nearly 24% of patients with advanced CKD, including those on dialysis, have gout, according to a study.
New analysis suggests that gout prevalence is 21% among patients on peritoneal dialysis and 13% among those on hemodialysis.
New findings complement previous research showing no renoprotective effect of urate-lowering therapy in patients with chronic kidney disease.
Hyponatremia and hypernatremia in patients hospitalized for COVID-19 are associated with increased odds of adverse outcomes.
Gout prevalence in Veterans Affairs medical centers increased from 4.2% in 2005 to 5.8% in 2014.
Patients with asymptomatic hyperuricemia who achieved serum uric acid levels of 6.0 mg/dL or less while on urate-lowering therapy had fewer gout flare episodes, a study found.
Each 1 mg/dL rise in uric acid level was significantly associated with a 21% and 10% increased risk for cardiovascular and all-cause mortality, respectively, a study found.
Hyperuricemia and gout may be associated with a lower risk for Alzheimer disease.
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Nearly two-thirds of hospitalized patients with COVID-19 and acute kidney injury requiring dialysis died during their hospital stay, a study found.
